The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling

Brijal Desai(The Wistar Institute), Meenhard Herlyn(The Wistar Institute)
PLoS ONE
March 18, 2013
Cited by 63


Related Papers